126 related articles for article (PubMed ID: 38128174)
21. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study.
Jeong S; Choi S; Park SM; Kim J; Ghang B; Lee EY
Arthritis Res Ther; 2022 Jul; 24(1):180. PubMed ID: 35902964
[TBL] [Abstract][Full Text] [Related]
22. Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study.
Westermann R; Cordtz RL; Duch K; Mellemkjaer L; Hetland ML; Burden AM; Dreyer L
Rheumatology (Oxford); 2024 Jan; 63(1):93-102. PubMed ID: 37052534
[TBL] [Abstract][Full Text] [Related]
23. Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study.
Yoshida S; Miyata M; Suzuki E; Kanno T; Sumichika Y; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
Front Immunol; 2023; 14():1267749. PubMed ID: 37868999
[TBL] [Abstract][Full Text] [Related]
24. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
Huss V; Bower H; Hellgren K; Frisell T; Askling J; ;
Ann Rheum Dis; 2023 Jul; 82(7):911-919. PubMed ID: 36868796
[TBL] [Abstract][Full Text] [Related]
25. A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort.
Tageldin M; Wilson N; Yin Y; Sharma TS
Rheumatology (Oxford); 2023 Oct; 62(Suppl_4):iv8-iv13. PubMed ID: 37855679
[TBL] [Abstract][Full Text] [Related]
26. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
[TBL] [Abstract][Full Text] [Related]
27. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
Hellgren K; Di Giuseppe D; Smedby KE; Sundström C; Askling J; Baecklund E;
Rheumatology (Oxford); 2021 Feb; 60(2):809-819. PubMed ID: 32810256
[TBL] [Abstract][Full Text] [Related]
28. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study.
Huang Y; Agarwal SK; Chen H; Chatterjee S; Johnson ML; Aparasu RR
Clin Ther; 2023 Sep; 45(9):e177-e186. PubMed ID: 37573225
[TBL] [Abstract][Full Text] [Related]
29. A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy.
Wong PKK; Bagga H; Barrett C; Chong G; Hanrahan P; Kodali T; Marabani M; Prince HM; Riordan J; Swarbrick P; White R; Young L
Curr Rheumatol Rep; 2018 Sep; 20(10):64. PubMed ID: 30173305
[TBL] [Abstract][Full Text] [Related]
30. Biologic therapy is associated with malignancies among Israeli patients with rheumatoid arthritis: A population-based study.
Katony Eizenstat E; Hassan F; Golan Cohen A; Merzon E; Green I; Paz Z; Naffaa ME
Int J Rheum Dis; 2023 Jul; 26(7):1330-1336. PubMed ID: 37269484
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: real-world data from the KOBIO Registry.
Koh JH; Lee SK; Kim J; Kim HA; Shin K; Min JK
Clin Exp Rheumatol; 2021; 39(2):269-278. PubMed ID: 32324126
[TBL] [Abstract][Full Text] [Related]
32. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Sepriano A; Kerschbaumer A; Bergstra SA; Smolen JS; van der Heijde D; Caporali R; Edwards CJ; Verschueren P; de Souza S; Pope J; Takeuchi T; Hyrich K; Winthrop KL; Aletaha D; Stamm T; Schoones JW; Landewé RBM
Ann Rheum Dis; 2023 Jan; 82(1):107-118. PubMed ID: 36376026
[TBL] [Abstract][Full Text] [Related]
33. Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010.
Ichinose K; Shimizu T; Umeda M; Fukui S; Nishino A; Koga T; Kawashiri SY; Iwamoto N; Tamai M; Nakamura H; Sato S; Origuchi T; Kawakami A
J Immunol Res; 2018; 2018():6259010. PubMed ID: 30186881
[TBL] [Abstract][Full Text] [Related]
34. COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs.
Tsai JJ; Liu LT; Chen CH; Chen LJ; Wang SI; Wei JC
RMD Open; 2023 Jul; 9(3):. PubMed ID: 37479495
[TBL] [Abstract][Full Text] [Related]
35. Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis.
Holdsworth EA; Donaghy B; Fox KM; Desai P; Collier DH; Furst DE
Rheumatol Ther; 2021 Dec; 8(4):1637-1649. PubMed ID: 34487340
[TBL] [Abstract][Full Text] [Related]
36. Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry.
Min HK; Kim HR; Lee SH; Shin K; Kim HA; Park SH; Kwok SK
Clin Rheumatol; 2021 Aug; 40(8):3105-3113. PubMed ID: 33576925
[TBL] [Abstract][Full Text] [Related]
37. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register.
Redeker I; Albrecht K; Kekow J; Burmester GR; Braun J; Schäfer M; Zink A; Strangfeld A
Ann Rheum Dis; 2022 Jan; 81(1):41-47. PubMed ID: 34321218
[TBL] [Abstract][Full Text] [Related]
38. Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases.
Pombo-Suárez M; Seoane-Mato D; Díaz-González F; Sánchez-Alonso F; Sánchez-Jareño M; Cea-Calvo L; Castrejón I
Adv Rheumatol; 2023 Jun; 63(1):25. PubMed ID: 37287051
[TBL] [Abstract][Full Text] [Related]
39. Inflammation-targeted therapies and cancer.
Kedra J; Nocturne G; Mariette X; Seror R
Joint Bone Spine; 2021 Jul; 88(4):105176. PubMed ID: 33771759
[TBL] [Abstract][Full Text] [Related]
40. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
